Skip to main content

Advertisement

SpringerLink
Log in

Utility of CA 125 in Determining the Response to Neoadjuvant Chemotherapy

  • Original Article
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Background

CA-125 is the tumor marker for surface epithelial carcinoma of ovary, and it is used to determine the response to chemotherapy, relapse, and disease progression. Neoadjuvant chemotherapy followed by interval debulking surgery is an acceptable treatment for patients with advanced disease. Most patients will require 2–4 cycles of neoadjuvant chemotherapy. However, some patients receive more than 4 cycles of neoadjuvant chemotherapy in many centers, and the most common reason for this is extensive disease at the beginning of neoadjuvant chemotherapy.

Purpose

To determine if a normal CA-125 level following neoadjuvant chemotherapy is an indicator of satisfactory reduction in the extent of the disease and should CA-125 levels be considered in deciding the number of cycles of neoadjuvant chemotherapy.

Methods

The histopathology report of all patients who underwent successful interval cytoreduction between 01-09-2020 and 31-08-2021 was analyzed to determine if the preoperative CA-125 level following neoadjuvant chemotherapy is reflective of the extent of disease resolution.

Results

There was no correlation between the pre-neoadjuvant chemotherapy CA-125 level, pre-operative CA-125 level, and the histopathology report. Some patients with a very high pre-neoadjuvant chemotherapy and pre-operative CA-125 level had no extra-ovarian involvement. Conversely, some patients with a low pre-neoadjuvant chemotherapy and a pre-operative CA-125 level had significant extra-ovarian involvement.

Conclusion

After how many cycles of neoadjuvant chemotherapy should surgery be performed must be decided by clinical examination and imagining. The purpose of neoadjuvant chemotherapy is to increase the rate of achieving complete cytoreduction in patients with extensive disease and poor performance status. Administering more than 3–4 cycles can be counterproductive.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.

    Article  Google Scholar 

  2. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75(4):264–5.

    Article  CAS  Google Scholar 

  3. Asher V, Hammond R, Duncan TJ. Pelvic mass associated with raised CA 125 for benign condition: a case report. World J Surg Onc. 2010;8:28.

    Article  Google Scholar 

  4. Rao S, Kapurubandara S, Anpalagan A. Elevated CA 125 in a case of leaking endometrioma. Case Reports in Obstetrics and Gynecology, vol. 2018

  5. Marci CI, Vasilev SA. Highly elevated CA125 and tubo-ovarian abscess mimicking ovarian carcinoma. Gynecol Obstet Invest. 1994;37:143–4.

    Article  Google Scholar 

  6. Ghaemmaghami F, Karimi Zarchi M, Hamedi B. High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet. 2007;276:559–61.

    Article  Google Scholar 

  7. Menczer J, Ben-Shem E, Golan A, Levy T. The significance of normal pretreatment levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma. Rambam Maimonides Med J. 2015; 6(1): e0005

  8. Choi JH, Sohn GS, Chay DB, Cho HB, Kim J. Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. Obstet Gynecol Sci. 2018;61(3):344–51.

    Article  Google Scholar 

  9. Greer BE, Swensen RE, Gray HJ. Surgery for ovarian cancer: rationale and guidelines. J Natl Compr Canc Netw. 2004;2(6):561–8.

    Article  Google Scholar 

  10. Liakou CG, Akrivos N, Kumar B, Duncan TJ, Turnbull HL, Nieto JJ, Burbos N. Cholecystectomy as part of cytoreductive surgery for advanced ovarian cancer: perioperative outcomes. Anticancer Res. 2020;40(4):2331–6.

    Article  CAS  Google Scholar 

  11. Derlatka P, Sienko J, Grabowska-Derlatka L, et al. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Onc. 2016;14:58.

    Article  Google Scholar 

  12. Bentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N, Morice P. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol. 2016;27(11):1994–2004.

    Article  CAS  Google Scholar 

  13. Schorge JO, McCann C, Del Carmen MG. Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol. 2010 Summer; 3(3):111–7

  14. Gao Y, et al. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2019;12:85.

    Article  Google Scholar 

  15. Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol. 2014;6(6):293–304.

    Article  CAS  Google Scholar 

  16. Liu YL, et al. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. Int J Gynecol Cancer. 2020. https://doi.org/10.1136/ijgc-2020-001641.

  17. Wang D, et al. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2021;14:49.

    Article  Google Scholar 

  18. Heller D, Cracchiolo B. Histopathologic alterations in ovarian papillary serous cystadenocarcinomas after neoadjuvant chemotherapy: possible clinical significance. J Gynecol Surg. 2017;33(1):1–3.

    Article  Google Scholar 

  19. Ferron JG, et al. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):101–5.

    Article  CAS  Google Scholar 

  20. Liu J, Jiao X, Gao Q. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. Drug Discov Today. 2020;25(7):1232–8.

    Article  CAS  Google Scholar 

  21. Vermeulen CKM, Tadesse W, Timmermans M, Kruitwagen RFPM, Walsh T. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2017;219:100–5.

    Article  Google Scholar 

  22. Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, Mahavir Cancer Sansthan, Patna, 801505, India

    Neelu Yadav & Anirudha Rohit Podder

Authors
  1. Neelu Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anirudha Rohit Podder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anirudha Rohit Podder.

Ethics declarations

Conflict of interest

Both the authors declare that they have no conflict of interest.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yadav, N., Podder, A.R. Utility of CA 125 in Determining the Response to Neoadjuvant Chemotherapy. Indian J Gynecol Oncolog 20, 19 (2022). https://doi.org/10.1007/s40944-022-00622-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-022-00622-3

Keywords

Search

Navigation